Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Memphis, Tennessee 38138


Purpose:

The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.


Criteria:

Inclusion Criteria: - Histologically or cytologically confirmed adenocarcinoma of the prostate which is metastatic and/or unresectable - Hormone refractory prostate cancer defined as progressive based by documented 2 increase PSA values over a previous reference value. - ECOG status 0-2 - Adequate hematological functions, liver and renal functions Exclusion Criteria: - Known hypersensitivity to docetaxel or taxane therapy - Documented central nervous system or leptomeningeal metastasis at time of study entry - Had prior treatment with chemotherapy, bone seeking radionucleides in past 6 weeks prior to enrollment, or radiotherapy involving more than 25% of marrow producing area. - Evidence of painful and/or destructive bone metastases for which radiation therapy, biophosphonates or boneseeking radionucleides are necessary. - Have received treatment in the last 30 day with a drug which has not received regulatory approval for any indication at the time of study entry.


NCT ID:

NCT00642018


Primary Contact:

Study Director
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM Eastern time (UTC/GMT-5 hours, EST)
Eli Lilly and Company


Backup Contact:

N/A


Location Contact:

Memphis, Tennessee 38138
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 17, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.